A survey of pharmaceutical company representative interactions with doctors in Libya

Libyan Journal of Medicine

Volumn 7, Issue 1, 2012, Pages

  Alssageer, Mustafa A ^a   Kowalski, Stefan R ^b  

^a SEBHA UNIVERSITY   (Libyan Arab Jamahiriya)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Gift giving; Pharmaceutical promotion; Pharmaceutical representative visits

Indexed keywords

ADULT; AGE; AGED; ANESTHESIST; CONTROLLED STUDY; FEMALE; GENERAL PRACTITIONER; GIFT GIVING; HUMAN; HUMAN RELATION; LIBYAN ARAB JAMAHIRIYA; MALE; MEDICAL PRACTICE; NONMEDICAL OCCUPATIONS; PHARMACEUTICAL COMPANY REPRESENTATIVE; PHYSICIAN; PRIVATE PRACTICE; QUESTIONNAIRE; REIMBURSEMENT; RESIDENT; REVIEW; SEX DIFFERENCE; SOCIAL INTERACTION; SURGEON; WORK EXPERIENCE;

EID: 84866979288     PISSN: 19932820     EISSN: 18196357     Source Type: Journal    
DOI: 10.3402/ljm.v7i0.18556     Document Type: Review

References (86)

1. Wilson D. Drug companies increase prices in face of change. NewYork Times, 16 November 2009, A1. Available from: http:// www.nytimes.com/2009/11/16/business/16drugprices.html?_r_1 [downloaded 15 November 2009].
2. Parry TG, Creyke P. The Australian pharmaceutical industry: achievements, prospects and the policy environment. North Sydney: Australian Pharmaceutical Manufacturers Association; 1991.
3. Kaiser Family Foundation. Trends and indicators in the changing health care marketplace; 2005. Available from: http://www. kff.org/insurance/7031/ti2004-1-20.cfm [downloaded 2 August 2006].
4. Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996; 5: 201_6.
5. Greenwood J. Marketing medicine: what works and why. London: Remit Consultant Ltd; 1991.
6. Kisa A. The performance and problems of the Turkish pharmaceutical industry: is there a need to develop a national drug policy? J Med Syst. 2001; 25: 309_18.
7. Randall T. Kennedy hearings say no more free lunch _ or much else _ from drug firms. JAMA. 1991; 265: 440_2.
8. Wolfe SM. Why do American drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? Characteristics of materials distributed by drug companies: four points of view. J Gen Intern Med. 1996; 11: 637_9.
9. Woosley RL. Centers for education and research in therapeutics. Clin Pharmacol Ther. 1994; 55: 249_55.
10. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement. BMJ. 2003; 326: 1189_92.
11. Wazana A. Physicians and the pharmaceutical industry _ is a gift ever just a gift? JAMA. 2000; 283: 373_80.
12. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004; 351: 1885_90.
13. Williams SC. Food for thought: why physicians should reconsider gifts from pharmaceutical companies. Curr Surg. 2003; 60: 152_3.
14. Marco CA, Moskop JC, Solomon RC, Geiderman JM, Larkin GL. Gifts to physicians from the pharmaceutical industry: an ethical analysis. Ann Emerg Med. 2006; 48: 513_21.
15. Morrison AW. 1999 LeTourneau award. An analysis of antikickback and self-referral law in modern health care. J Leg Med. 2000; 21: 351_94.
16. House of Commons Health Committee. The influence of the pharmaceutical industry. Available from: http://www.parliament. the-stationery-office.co.uk/pa/cm200405/cmselect/cmhealth/42/42. pdf [downloaded 5 April 2005].
17. Cialdini RB. Influence: science and practice. New York: Harper Collins College Publishers; 1993. p. 21.
18. SESRIC. Pharmaceutical industry production, consumption and trade in OIC member countries. Available from: http://www. sesric.org/website-search.php?cx_010499498461835971889%3 Amf5xgbwpfye&cof_FORID%3A11&q_pharmaceutical&siteurl_ http%3A%2F%2Fwww.sesric.org%2F [downloaded 29 September 2011].
19. Bolton L. Libyan health service capacity. London: The human development resource centre (HDRC). Available from: http:// hdrc.dfid.gov.uk/2011/02/libyan-health-service-capacity/ [downloaded 1 February 2011].
20. The Australian Trade Commission. Health and medical to Libya. Available from: http://austrade.gov.au/Health-and-medical-to-Libya/default.aspx [downloaded 22 April 2009].
21. Margolis LH. The ethics of accepting gifts from pharmaceutical companies. Pediatrics. 1991; 88: 1233_7.
22. Chren MM, Landefeld CS, Murray TH. Doctors, drug companies, and gifts. JAMA. 1989; 262: 3448_51.
23. Waud DR. Pharmaceutical promotions _ a free lunch? N Engl J Med. 1992; 327: 351_3.
24. Mainous AG 3rd, Hueston WJ, Rich EC. Patient perceptions of physician acceptance of gifts from the pharmaceutical industry. Arch Fam Med. 1995; 4: 335_9.
25. Blake RL Jr, Early EK. Patients' attitudes about gifts to physicians from pharmaceutical companies. J Am Board Fam Pract. 1995; 8: 457_64.
26. McCue JD, Hansen CJ, Gal P. Physicians' opinions of the accuracy, accessibility, and frequency of use of ten sources of new drug information. South Med J. 1986; 79: 441_3.
27. Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996; 5: 201_6.
28. Anderson BL, Silverman GK, Loewenstein GF, Zinberg S, Schulkin J. Factors associated with physicians' reliance on pharmaceutical sales representatives. Acad Med. 2009; 84: 994_1002.
29. Vancelik S, Beyhun NE, Acemoglu H, Calikoglu O. Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey. BMC Public Health. 2007; 25: 122.
30. Haayer F. Rational prescribing and sources of information. Soc Sci Med. 1982; 16: 2017_23.
31. Burashnikova IS, Ziganshin AU, Ziganshina LE. Attitudes to pharmaceutical promotion techniques among healthcare professionals in the Republic of Tatarstan, Russia. Int J Risk Saf Med. 2008; 20: 57_71.
32. Ben Abdelaziz A, Harrabi I, Rahmani S, Ghedira A, Gaha K, Ghannem H. Attitudes of general practitioners to pharmaceutical sales representatives in Sousse. East Mediterr Health J. 2003; 9: 1075_83.
33. Wang Y, Adelman RA. A study of interactions between pharmaceutical representatives and ophthalmology trainees. Am J Ophthalmol. 2009; 148: 619_622. e3.
34. Strang D, Gagnon M, Molloy W, Bedard M, Darzins P, Etchells E, et al. National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives. Ann R Coll Physicians Surg Can. 1996; 29: 474_8.
35. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 1296_8.
36. Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. Br J Gen Pract. 1994; 44: 220_3.
37. Reeder M, Dougherty J, White LJ. Pharmaceutical representatives and emergency medicine residents: a national survey. Ann Emerg Med. 1993; 22: 1593_6.
38. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med. 2007; 356: 1742_50.
39. Saito S, Mukohara K, Bito S. Japanese practicing physicians' relationships with pharmaceutical representatives: a national survey. PLoS One. 2010; 5: e12193.
40. Lieb K, Brandtönies S. A survey of german physicians in private practice about contacts with pharmaceutical sales representatives. Dtsch Arztebl Int. 2010; 107: 392_8.
41. The Kaiser Family Foundation. National survey of physicians part II: doctors and prescription drugs. Menlo Park, CA: Kaiser Family Foundation; 2002. http://www.kff.org/ rxdrugs/loader.cfm?url=/commonspot/security/getfile.cfm& PageID=13965 [downloaded September 2012].
42. Ijoma U, Onwuekwe I, Onodugo O, Aguwa E, Ejim E, Onyedum C, et al. Effect of promotional strategies of pharmaceutical companies on doctors' prescription pattern in Southeast Nigeria. TAF Prev Med Bull. 2010; 9: 1_6.
43. Norris P, Herxheimer A, Lexchin J, Mansfield P. Drug promotion: what we know, what we have yet to learn. Geneva: World Health Organization; 2005. Available from: http://www.who.int/ entity/medicines/areas/rational_use/drugPromodhai.pdf [downloaded 22 September 2006].
44. Ahmad M, Awan MHA, Murtaza G. Ethical evaluation of pharmaceutical marketing in Pakistan. Acta Bioethica. 2011; 17: 215_24.
45. Rohra DK, Gilani AH, Memon IK, Perven G, Khan MT, Zafar H, et al. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci. 2006; 9: 50_9.
46. Islam MS, Farah SS. Drug promotional brochure as a source of drug information in Bangladesh: a critical analysis of the brochures. Calicut Med J. 2008; 6: e5.
47. Roy N, Madhiwalla N, Pai SA. Drug promotional practices in Mumbai: a qualitative study. Indian J Med Ethics. 2007; 4: 57_61.
48. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract. 2003; 20: 61_8.
49. Caamaño F, Figueiras A, Gestal-Otero JJ. Influence of commercial information on prescription quantity in primary care. Eur J Public Health. 2002; 12: 187_91.
50. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry giftgiving. Am J Bioeth. 2003; 3: 39_46.
51. Reddy A. The role of 'self-concept' in industrial buying: an empirical investigation in the purchasing of office machines. University of North Carolina at Chapel Hill [dissertation]; 1971.
52. Simonson I, Huber J, Payne J. The relationship between prior brand knowledge and information acquisition order. J Consum Res. 1988; 14: 566_78.
53. Grande D, Frosch DL, Perkins AW, Kahn BE. Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med. 2009; 169: 887_93.
54. Groves KE, Sketris I, Tett SE. Prescription drug samples _ does this marketing strategy counteract policies for quality use of medicines? J Clin Pharm Ther. 2003; 28: 259_71.
55. Morgan MA, Dana J, Loewenstein G, Zinberg S, Schulkin J. Interactions of doctors with the pharmaceutical industry. J Med Ethics. 2006; 32: 559_63.
56. Gü ldal D, Semin S. The influences of drug companies' advertising programs on physicians. Int J Health Serv. 2000; 30: 585_95.
57. Spiller LD, Wymer WW. Physicians' perceptions and uses of commercial drug information sources. Health Mark Q. 2001; 19: 91_106.
58. Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ. 2003; 169: 405_12.
59. Lexchin J, Mintzes B. Direct-to-consumer advertising of prescription drugs: the evidence says no. J Public Policy Mark. 2002; 21: 194_201.
60. Warrier R, Monaghan MS, Maio A, Huggett K, Rich E. Effect of drug sample availability on physician prescribing behavior: a systematic review. Clin Rev Opin. 2010; 2: 41_8.
61. McNeill PM, Kerridge IH, Henry DA, Stokes B, Hill SR, Newby D, et al. Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Intern Med J. 2006; 36: 571_8.
62. Acar K, Zencir M, Ozsahin A, Cetin CB. Ethical problems of physicians in relationship with pharmaceutical representatives in Denizli, Turkey. Internet J Law Healthc Ethics. 2002; 1: 33.
63. Stern B, Gould S. The consumer as financial opinion leader. J Retail Bank. 1988; 10: 43_52.
64. Rogers EM. Diffusion of innovations. New York: The Free Press; 1995.
65. Curran GM, Thrush CR, Smith JL, Owen RR, Ritchie M, Chadwick D. Implementing research findings into practice using clinical opinion leaders: barriers and lessons learned. Jt Comm J Qual Patient Saf. 2005; 31: 700_7.
66. Nair H, Manchanda P, Bhatia T. Asymmetric social interactions in physician prescription behavior: the role of opinion leaders. J Marketing Res. 2010; 47: 883_95.
67. Haug JD. Physicians' preferences for information sources: a meta-analytic study. Bull Med Libr Assoc. 1997; 85: 223_32.
68. Thompson M. Characteristics of information resources preferred by primary care physicians. Bull Med Libr Assoc. 1997; 85: 187_92.
69. Kisa S. Factors that influence prescribing decisions among Turkish physicians. Clin Res Regul Aff. 2006; 23: 177_89.
70. Gunnarsdó ttir AI, Kinnear M. Factors that influence prescribers in their selection and use of COX-2 selective inhibitors as opposed to non-selective NSAIDs. Pharm World Sci. 2005; 27: 316_20.
71. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006; 145: 284_93.
72. de Vries CS, van Diepen NM, Tromp TF, de Jong-van den Berg LT. Auditing GPs' prescribing habits: cardiovascular prescribing frequently continues medication initiated by specialists. Eur J Clin Pharmacol. 1996; 50: 349_52.
73. Lexchin J. Doctors and detailers: therapeutic education or pharmaceutical promotion? Int J Health Serv. 1989; 19: 663_79.
74. Williams P, Cockerill R, Lowy F. The physician as prescriber: relations between knowledge about prescription drugs, encounters with patients and the pharmaceutical industry, and prescription volume. Health and Canadian Society. 1995; 3: 135_66.
75. Williams P, Cockerill R. Report on the 1989 survey of the prescribing experiences and attitudes toward prescription drugs of Ontario physicians. Toronto: Government of Ontario; 1990.
76. Roughead EE, Harvey KJ, Gilbert AL. Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Aust N Z J Med. 1998; 28: 306_10.
77. Eastern Mediterranean Regional Health Systems Observatory. Health system profile: Libya. Geneva: World Health Organization; 2007.
78. Otman WA, Karlberg E. Social policy and trends. In: Otman W, editor. The Libyan economy. Springer: Berlin; 2007, pp. 87_149.
79. Hemminki E, Pesonen T. The function of drug company representatives. Scand J Soc Med. 1977; 5: 105_14.
80. Pliner P, Hart H, Kohl J, Saari D. Compliance without pressure: some further data on the foot-in-the-door technique. J Exp Soc Psychol. 1974; 10: 17_22.
81. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982; 73: 4_8.
82. Watkins C, Moore L, Harvey I, Carthy P, Robinson E, Brawn R. Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study. BMJ. 2003; 326: 1178_9.
83. Schwartz TL, Kuhles DJ 2nd, Wade M. Masand PS. Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits. Ann Clin Psychiatry. 2001; 13: 159_62.
84. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988; 26: 1183_9.
85. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007; 4: e134.
86. World Health Organization. Ethical criteria for medicinal drug promotion. Geneva: World Health Organization; 1988. Available from: http://www.who.int/medicinedocs [downloaded 3 August 2008].